Table of Content
1. Executive Summary
2. Global Kidney Transplant Market Introduction
2.1. Global Kidney Transplant Market – Taxonomy
2.2. Global Kidney Transplant Market –Definitions
2.2.1. Immunosuppressive/rejection Drugs
2.2.2. Distribution Channel
3. Global Kidney Transplant Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Kidney Transplant Market Dynamic Factors - Impact Analysis
3.6. Global Kidney Transplant Market – Competition Landscape
3.7. Epidemiology
4. Global Kidney Transplant Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market OpportunityAnalysis
5. Global Kidney Transplant Market, By Immunosuppressive/rejection Drugs, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.1. Prograf (Tacrolimus)
5.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Myfortic (Mycophenolic Acid)
5.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Cellcept (Mycophenolate Mofetil)
5.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Zortress / Certican (Everolimus)
5.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Rapamune (Sirolimus)
5.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Neoral / Sandimmune (Cyclosporine)
5.6.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Kidney Transplant Market Forecast, By Distribution Channel,2013 - 2017 and Forecast, 2018 – 2024
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online Stores
6.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Kidney Transplant Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Kidney Transplant Market - Opportunity Analysis Index, By Immunosuppressive/rejection Drugs, By Distribution Channel and Region, 2018 – 2024
8. North America Kidney Transplant MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
8.1. Immunosuppressive/rejection Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
8.1.1. Prograf (Tacrolimus)
8.1.2. Myfortic (Mycophenolic Acid)
8.1.3. Cellcept (Mycophenolate Mofetil)
8.1.4. Zortress / Certican (Everolimus)
8.1.5. Rapamune (Sirolimus)
8.1.6. Neoral / Sandimmune (Cyclosporine)
8.2. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Stores
8.3. Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Kidney Transplant Market - Opportunity Analysis Index, By Immunosuppressive/rejection Drugs, By Distribution Channel and Country, 2018 – 2024
8.5. North America Kidney Transplant Market Dynamics – Trends
9. Europe Kidney Transplant Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
9.1. Immunosuppressive/rejection Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Prograf (Tacrolimus)
9.1.2. Myfortic (Mycophenolic Acid)
9.1.3. Cellcept (Mycophenolate Mofetil)
9.1.4. Zortress / Certican (Everolimus)
9.1.5. Rapamune (Sirolimus)
9.1.6. Neoral / Sandimmune (Cyclosporine)
9.2. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Stores
9.3. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Kidney Transplant Market - Opportunity Analysis Index, By Immunosuppressive/rejection Drugs, By Distribution Channel and Country, 2018 – 2024
9.5. Europe Kidney Transplant Market Dynamics – Trends
10. Asia-Pacific Kidney Transplant Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
10.1. Immunosuppressive/rejection Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Prograf (Tacrolimus)
10.1.2. Myfortic (Mycophenolic Acid)
10.1.3. Cellcept (Mycophenolate Mofetil)
10.1.4. Zortress / Certican (Everolimus)
10.1.5. Rapamune (Sirolimus)
10.1.6. Neoral / Sandimmune (Cyclosporine)
10.2. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Online Stores
10.3. Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Kidney Transplant Market - Opportunity Analysis Index, By Immunosuppressive/rejection Drugs, By Distribution Channel and Country, 2018 – 2024
10.5. Asia-Pacific Kidney Transplant Market Dynamics – Trends
11. Latin America Kidney Transplant Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
11.1. Immunosuppressive/rejection Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Prograf (Tacrolimus)
11.1.2. Myfortic (Mycophenolic Acid)
11.1.3. Cellcept (Mycophenolate Mofetil)
11.1.4. Zortress / Certican (Everolimus)
11.1.5. Rapamune (Sirolimus)
11.1.6. Neoral / Sandimmune (Cyclosporine)
11.2. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Online Stores
11.3. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Kidney Transplant Market - Opportunity Analysis Index, By Immunosuppressive/rejection Drugs, By Distribution Channel and Country, 2018 – 2024
11.5. Latin America Kidney Transplant Market Dynamics – Trends
12. Middle East and Africa Kidney Transplant Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
12.1. Immunosuppressive/rejection Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Prograf (Tacrolimus)
12.1.2. Myfortic (Mycophenolic Acid)
12.1.3. Cellcept (Mycophenolate Mofetil)
12.1.4. Zortress / Certican (Everolimus)
12.1.5. Rapamune (Sirolimus)
12.1.6. Neoral / Sandimmune (Cyclosporine)
12.2. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.2.3. Online Stores
12.3. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Kidney Transplant Market - Opportunity Analysis Index, By Immunosuppressive/rejection Drugs, By Distribution Channel and Country, 2018 – 2024
12.5. MEA Kidney Transplant Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Immunosuppressive/rejection Drugs& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Veloxis Pharmaceuticals A/S (Denmark)
13.2.2. Sanofi (France)
13.2.3. Immucor, Inc. (U.S)
13.2.4. Biocon Ltd. (India)
13.2.5. Novartis AG (Switzerland)
13.2.6. Pfizer, Inc. (U.S.)
13.2.7. Astellas Pharma (U.S.)
13.2.8. Hoffmann La Roche Ltd. (Switzerland)
14. Research Methodology
15. Key Assumptions and Acronyms